Material Agreements

IB Acquisition Corp. entered into Registration Rights Agreement with certain security holders (effective 2024-03-25).

“Registration Rights Agreement, dated March 25, 2024, by and among the Company and certain security holders, a copy of which is attached”

IB Acquisition Corp. entered into Investment Management Trust Agreement with Continental Stock Transfer & Trust Company (effective 2024-03-25).

“An Investment Management Trust Agreement, dated March 25, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as trustee”

IB Acquisition Corp. entered into Rights Agreement with Continental Stock Transfer & Trust Company (effective 2024-03-25).

“A Rights Agreement, dated March 25, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as rights agent”

IB Acquisition Corp. entered into Underwriting Agreement with I-Bankers Securities, Inc. valued at $115,000,000 (effective 2024-03-25).

“An Underwriting Agreement, dated March 25, 2024, by and between the Company and I-Bankers Securities, Inc., as representative of the several underwriters”

Bitcoin Depot Inc. amended Amendment No. 1 valued at $15,700,000 (effective 2024-03-26).

“On March 26, 2024, Bitcoin Depot Operating LLC, a Delaware limited liability company (“BT OpCo”) and BT HoldCo LLC, a Delaware limited liability company (“BT HoldCo”) entered into that certain Amendment No. 1 (the “Amendment”) to the Amended and Restated Credit Agreement, dated June 23, 2023 (the “Credit Agreement”) with the Lenders (as defined in the Credit Agreement).”

Blue World Acquisition Corp amended Investment Management Trust Agreement with Continental Stock Transfer & Trust Company valued at The Trustee must commence liquidation of the Company's trust account by April 2, 2024, or, if furthe (effective 2024-03-26).

“Item 1.01. Entry into a Material Definitive Agreement. On March 26, 2024, Blue World Acquisition Corporation, a Cayman Islands exempted company (the “ Company ”) held an extraordinary general meeting in lieu of an annual general meeting of shareholders (the “ Shareholder Meeting ”), where the shareholders of the Company approved by way of special resolution, among others, the Company to amend the Investment Management Trust Agreement dated January 31, 2022, as amended on May 2, 2023, June 30, 2023 and January 26, 2024 (the “ Trust Agreement ”), by and between the Company and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the “ Trustee ”) to provide that the Trustee must commence liquidation of the Company’s trust account (the “ Trust Account ”) by April 2, 2024, or, if further extended by up to seven one-month extensions (the “ Monthly Extension ”), up to November 2, 2024. Upon the shareholders’ approval, on March 26, 2024, the Company and the Tru”

APx Acquisition Corp. I entered into Business Combination Agreement with OmnigenicsAI Corp, Heritas Merger Sub Limited, and MultiplAI Health Ltd (effective 2024-03-25).

“On March 25, 2024, APx Acquisition Corp. I (the “Company”), OmnigenicsAI Corp, a Cayman Islands exempted company (“OmnigenicsAI”), Heritas Merger Sub Limited, a Cayman Islands exempted company and a direct wholly-owned subsidiary of OmnigenicsAI (“Merger Sub”) and MultiplAI Health Ltd, a private limited company formed under the laws of England and Wales (“MultiplAI” and, together with OmnigenicsAI, the “Target Companies”), entered into a Business Combination Agreement (the “Business Combination Agreement””

Advanced Flower Capital Inc. amended Amendment with the lenders party thereto and the lead arranger, bookrunner and administrative agent party thereto (effective 2024-03-26).

“On March 26, 2024, AFC Gamma, Inc., a Maryland corporation (the “Company”) entered into an amendment (the “Amendment”) to the Loan and Security Agreement, dated as of April 29, 2022, by and among the lenders party thereto and the lead arranger, bookrunner and administrative agent party thereto.”

Renalytix plc amended Bond Agreement Amendment with CVI Investments, Inc. (effective 2024-03-28).

“On March 28, 2024, Renalytix plc (the “ Company ”) entered into a second amendment and restatement agreement (“ Bond Agreement Amendment ”) with CVI Investments, Inc. (" CVI "), which amended the terms of the Company’s existing bond agreement”

Vincerx Pharma, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $50,000,000 (effective 2024-03-29).

“On March 29, 2024, Vincerx Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (the “Sales Agent”).”

Greenbrook TMS Inc. entered into Twenty-Eighth Amendment with Madryn Fund Administration, LLC valued at US$2,614,213 (effective 2024-03-28).

“On March 28, 2024, the Company entered into the twenty-eighth amendment (the “ Amendment ”) to the Company’s credit agreement”

Monroe Capital Income Plus Corp entered into Credit Agreement with Goldman Sachs Bank USA valued at $100 million (effective 2024-03-28).

“On March 28, 2024, Monroe Capital Income Plus Corporation (the “Company”) entered into a senior secured term credit facility (the “Credit Facility”) with Goldman Sachs Bank USA through a newly-created wholly-owned subsidiary, MC Income Plus Financing SPV III LLC (the “SPV”). In connection with this Credit Facility, the Company, as collateral manager, the SPV, as borrower, and each of the other parties thereto entered into a Credit Agreement, dated as of March 28, 2024 (the “Credit Agreement”).”

NetBrands Corp. entered into Securities Purchase Agreement with Cove Funding LP valued at up to $300,000 (effective 2024-03-22).

“On March 22, 2024 (the “Closing Date”), NetBrands Corp., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Cove Funding LP, a Delaware limited partnership (“Cove Funding”), pursuant to which Cove Funding agreed to loan the Company up to $300,000, in two tranches (the “Cove Loan”), and the Company issued Cove Funding a 12% Senior Secured Convertible Promissory Note (the “Convertible Note”) to evidence the Cove Loan.”

Doma Holdings, Inc. entered into Agreement and Plan of Merger with RE Closing Buyer Corp. and RE Closing Merger Sub Inc. (effective 2024-03-28).

“On March 28, 2024, Doma Holdings, Inc. (the “ Company ” or “ Doma ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), with RE Closing Buyer Corp., a Delaware corporation (“ Parent ”), and RE Closing Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (the “ Merger Sub ”).”

Alzamend Neuro, Inc. entered into Agreement with Ault Lending, LLC valued at purchase price of $2.0 million (effective 2024-01-31).

“On March 26, 2024, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”) entered into with Ault Lending, LLC, a California limited liability company (the “ Purchaser ”) on January 31, 2024”

SCWorx Corp. terminated Agreement and Plan of Merger with American Environmental (effective 2024-03-26).

“CWorx entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with American Environmental. The material”

Medpace Holdings, Inc. amended Amendment No. 6 to Loan Documents with PNC Bank, National Association valued at up to $10 million (effective 2024-03-28).

“Medpace Holdings, Inc., a Delaware corporation (the "Company"), through its wholly owned subsidiaries, Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No. 6 to Loan Documents (“Amendment No. 6”) with PNC Bank, National Association”

Audax Credit BDC Inc. entered into Subscription Agreement with Mercer Audax Credit Feeder Fund LP valued at $37.0 million (effective 2024-03-25).

“Effective March 25, 2024, Audax Credit BDC Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with Mercer Audax Credit Feeder Fund LP, the Company’s controlling shareholder (the “Investor”), pursuant to which the Investor has made a capital commitment in respect of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in an amount equal to $37.0 million.”

Celcuity Inc. amended Second Amendment with Innovatus Life Sciences Lending Fund I, L.P. (effective 2024-03-29).

“On March 29, 2024, Celcuity Inc. (the “Company”) entered into a Second Amendment (the “Second Amendment”) to its existing Loan and Security Agreement (the “Loan Agreement”), dated April 8, 2021, between the Company and Innovatus Life Sciences Lending Fund I, L.P., a Delaware limited partnership (“Innovatus")”

TON Strategy Co amended Second Amendment to At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at $9,010,000 increase to ATM Offering (effective 2024-03-29).

“On March 29, 2024, the Company entered into the Second Amendment to At-The-Market Issuance Sales Agreement, dated March 29, 2024 (the " Amendment ") to increase the number of shares to be sold in the ATM Offering to $9,010,000”

Spirit Aviation Holdings, Inc. entered into Agreement with International Aero Engines, LLC (IAE) valued at between $150 million and $200 million (effective 2024-03-26).

“On March 26, 2024, Spirit entered into an agreement with International Aero Engines, LLC ("IAE"), an affiliate of Pratt & Whitney (the “Agreement”) pursuant to which IAE will provide Spirit with a monthly credit through the end of 2024, subject to certain conditions, as compensation for each Spirit aircraft unavailable for operational service due to GTF engine issues.”

Tonix Pharmaceuticals Holding Corp. entered into Purchase Agreement with certain institutional investors valued at up to approximately $4.4 million (effective 2024-03-28).

“On March 28, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).”

Clean Vision Corp amended Amended and Restated Warrant to Purchase Common Stock with Investor (effective 2024-03-25).

“In connection with the Purchase Agreement, the Company and Investor agreed to amend and restate the Existing Warrant as set forth in that certain Amended and Restated Warrant to Purchase Common Stock dated March 25, 2024 (the “A&R Warrant).”

Clean Vision Corp amended Amended and Restated Convertible Note with Investor (effective 2024-03-25).

“In connection with the Purchase Agreement, the Company and Investor amended and restated the Existing Note as set forth in that certain Amended and Restated Convertible Note dated March 25, 2024 (the “A&R Note).”

Clean Vision Corp entered into Registration Rights Agreement with Investor (effective 2024-03-25).

“On the Issue Date, the Company and the Investor entered into a registration rights agreement (the “RRA”), pursuant to which the Company agreed to file with the SEC, within forty-five (45) days after the Issue Date, a registration statement covering the resale of all securities issuable to the Investor under the Purchase Agreement.”

Clean Vision Corp entered into Securities Purchase Agreement with Investor (effective 2024-03-25).

“On March 25, 2024 (the “Issue Date”), the Company and Investor entered into a Securities Purchase Agreement (the “Purchase Agreement”), whereby: (i) the Company issued to the Investor (a) a convertible note in the aggregate principal amount of $666,666 (the “March 2024 Note”), and (b) a warrant initially exercisable to acquire up to 22,222,220 shares of Common Stock at an exercise price of $0.03 per share (the “March 2024 Warrant”); and (ii) the parties agreed to amend and restate the Existing Note and Existing Warrant as discussed below.”

MAGNACHIP SEMICONDUCTOR Corp entered into Standard Credit Agreement with Korea Development Bank valued at KRW 40,000,000,000 (approximately $28.9 million) (effective 2024-03-26).

“executed a Standard Credit Agreement (together with its General Terms and Conditions, the “Loan Agreement”) with Korea Development Bank (“KDB”).”

FIVE STAR BANCORP entered into Underwriting Agreement with Keefe, Bruyette & Woods, Inc. valued at 3,450,000 shares of common stock at $21.75 per share (effective 2024-03-28).

“On March 28, 2024, Five Star Bancorp (the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the “Bank”), entered into an underwriting agreement (the “Underwriting Agreement”) with Keefe, Bruyette & Woods, Inc., as representative of the several underwriters named in Schedule I thereto (collectively, the “Underwriters”), to issue and sell 3,450,000 shares of the Company’s common stock, no par value (“Common Stock”), at a public offering price of $21.75 per share in an underwritten public offering (the “Offering”).”

PROVIDENT FINANCIAL SERVICES INC amended Second Amendment with Lakeland Bancorp, Inc. (effective 2024-03-29).

“On March 29, 2024, Provident Financial Services, Inc., a Delaware corporation (“Provident”), NL 239 Corp., a Delaware corporation and a direct, wholly owned subsidiary of Provident (“Merger Sub”), and Lakeland Bancorp, Inc., a New Jersey corporation (“Lakeland”), entered into Amendment No. 2 (the “Second Amendment”) to that certain Agreement and Plan of Merger (the “Original Merger Agreement”), dated as of September 26, 2022, by and among Provident, Merger Sub and Lakeland, as amended by Amendment No. 1 to the Original Merger Agreement, dated as of December 20, 2023 (the “First Amendment” and the Original Merger Agreement, as amended by the First Amendment and the Second Amendment, the “Merger Agreement”), by and among Provident, Merger Sub and Lakeland.”

LIGHTBRIDGE Corp amended Modification No. 2 with Battelle Energy Alliance, LLC valued at approximately $635,000 (effective 2024-03-26).

“On March 26, 2024, Lightbridge Corporation (“Lightbridge” or the “Company”) and Battelle Energy Alliance, LLC (“Battelle”), the operating contractor of Idaho National Laboratory, entered into Modification No. 2 (“Modification No. 2”) to the Project Task Statement under the Strategic Partnership Project Agreement, dated December 9, 2022, as amended on May 23, 2023, by and between the Company and Battelle.”

UNITED THERAPEUTICS Corp entered into Credit Agreement with Wells Fargo Bank, National Association valued at up to $1.2 billion (effective 2022-03-31).

“on March 31, 2022, United Therapeutics Corporation (the Company ) entered into a Credit Agreement (the Credit Agreement ) with certain of its subsidiaries party thereto, as guarantors, the lenders referred to therein, and Wells Fargo Bank, National Association ( Wells Fargo ), as administrative agent and as a swingline lender.”

ENTERPRISE PRODUCTS PARTNERS L.P. entered into 364-Day Revolving Credit Agreement with Citibank, N.A., as Administrative Agent, and certain financial institutions named therein, as Co-Syndication Agents and Co-Documentation Agents valued at $1.5 billion (effective 2024-03-29).

“On March 29, 2024, Enterprise Products Operating LLC, a Texas limited liability company (“EPO”) and the operating subsidiary of Enterprise Products Partners L.P., a Delaware limited partnership (the “Partnership”), entered into a 364-Day Revolving Credit Agreement among EPO, as Borrower, the Lenders party thereto, Citibank, N.A., as Administrative Agent, and certain financial institutions named therein, as Co-Syndication Agents and Co-Documentation Agents (the “364-Day Credit Agreement”).”

NextPlat Corp entered into Stock Purchase Agreement with James T. McKinley valued at $760,000.00 (effective 2024-03-25).

“On March 25, 2024, NextPlat Corp (NASDAQ: NXPL, NXPLW) (the “Company” or “NextPlat”) entered into a Stock Purchase Agreement (the “SPA”) with James T. McKinley (“Seller”), pursuant to which the Company agreed to purchase all of the issued and outstanding shares of common stock of Outfitter Satellite, Inc. (“Outfitter”) in an all-cash transaction (the “Acquisition”) for an aggregate purchase price of $760,000.00”

OPKO HEALTH, INC. entered into Asset Purchase Agreement with Laboratory Corporation of America Holdings valued at approximately $237,500,000 in cash (effective 2024-03-27).

“On March 27, 2024, OPKO Health, Inc., a Delaware corporation (“ OPKO ”), its wholly owned subsidiary, BioReference Health, LLC (“ BioReference ” and together with OPKO, “ Seller ”), and Laboratory Corporation of America Holdings, a Delaware corporation (“ Buyer ”), entered into an Asset Purchase Agreement (the “ Purchase Agreement ”).”

AMERICAN HONDA FINANCE CORP entered into Third Amended and Restated Credit Agreement with Canadian Imperial Bank of Commerce, as administrative agent, joint bookrunner and co-lead arranger; RBC Capital Markets, as joint bookrunner and co-lead arranger; BMO Capital Markets, as joint bookrunner and co-lead arranger; The Toronto-Dominion Bank, as co-arranger and co-syndication agent; MUFG B valued at C$2,000,000,000 ($1,472,428,771) (effective 2024-03-25).

“On March 25, 2024, Honda Canada Finance Inc. (“HCFI”), a subsidiary of American Honda Finance Corporation, entered into its C$2,000,000,000 ($1,472,428,771) Third Amended and Restated Credit Agreement, among HCFI, as the borrower, the lenders party thereto, and Canadian Imperial Bank of Commerce, as administrative agent, joint bookrunner and co-lead arranger, RBC Capital Markets, as joint bookrunner and co-lead arranger, BMO Capital Markets, as joint bookrunner and co-lead arranger, The Toronto-Dominion Bank, as co-arranger and co-syndication agent, MUFG Bank, Ltd., Canada Branch, as co-arranger and co-syndication agent, Bank of Montreal, as co-syndication agent, Royal Bank of Canada, as co-syndication agent, Mizuho Bank, Ltd., Canada Branch, as documentation agent (the “Credit Agreement”).”

Mosaic ImmunoEngineering Inc. terminated License Agreement with Case Western Reserve University (effective 2024-03-22).

“on March 22, 2024, the Company received a letter of termination from CWRU terminating our Agreement effective immediately due to our financial default”

CLEANSPARK, INC. amended Amendment No. 1 to the At the Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $800,000,000 (effective 2024-03-28).

“On March 28, 2024, the Company entered into Amendment No. 1 to the At the Market Offering Agreement with the Agent (the “ATM Agreement Amendment” and, together with the Original ATM Agreement, the “ATM Agreement”). Under the ATM Agreement, the Company may, but has no obligation to, following the filing date of the Prospectus Supplement (as defined below), issue and sell up to the lesser number of shares (the “Shares”) of the Company’s Common Stock, that does not exceed (a) $800,000,000 of shares of Common Stock”

VIASAT INC amended Refinancing Amendment with Barclays Bank plc, Bank of America, N.A., and the lenders and issuing banks party thereto (effective 2024-03-28).

“On March 28, 2024, Connect Midco Limited (“Holdings”), Connect Bidco Limited (“Bidco”), Connect Finco SARL (“Lux Finco”), Connect U.S. Finco LLC (“US Finco”) and certain other subsidiary loan parties (collectively, with Holdings, Bidco, Lux Finco and US Finco, “Inmarsat,” and all indirect wholly owned subsidiaries of Viasat, Inc. (“Viasat”)) entered into Amendment No. 4 to Credit Agreement with Barclays Bank plc, as existing administrative agent and collateral agent, Bank of America, N.A., as successor administrative agent and collateral agent, and the lenders and issuing banks party thereto (the “Refinancing Amendment”) to amend the existing Credit Agreement”

OLD REPUBLIC INTERNATIONAL CORP entered into Eighth Supplemental Indenture with Wilmington Trust Company, as trustee valued at $400,000,000 (effective 2024-03-28).

“The Company issued the Notes under an indenture dated as of August 15, 1992 (the “Base Indenture”), as supplemented by an eighth supplemental indenture dated as of March 28, 2024 (the “Eighth Supplemental Indenture” and, together with the Base Indenture, the “Indenture”), each between the Company and Wilmington Trust Company, as trustee (the “Trustee”).”

OLD REPUBLIC INTERNATIONAL CORP entered into Underwriting Agreement with Morgan Stanley & Co. LLC and PNC Capital Markets LLC, as representatives of the several underwriters valued at $400,000,000 (effective 2024-03-25).

“On March 25, 2024, Old Republic International Corporation (the “Company”) priced a registered underwritten public offering of 5.750% Senior Notes due 2034 in the aggregate principal amount of $400,000,000 (the “Notes”) to be sold pursuant to an underwriting agreement that was entered into among the Company, and Morgan Stanley & Co. LLC and PNC Capital Markets LLC, as representatives of the several underwriters named therein, dated March 25, 2024 (the “Underwriting Agreement”).”

HOME DEPOT, INC. entered into Agreement and Plan of Merger with Shingle Acquisition Holdings, Inc., a Delaware corporation valued at $18,250,000,000 (effective 2024-03-27).

“On March 27, 2024, The Home Depot, Inc., a Delaware corporation (the " Company "), Star Acquisition Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of the Company (" Merger Sub "), Shingle Acquisition Holdings, Inc., a Delaware corporation (" SRS "), and Shingle Acquisition, LP, a Delaware limited partnership, solely in its capacity as the initial Holder Representative, entered into an Agreement and Plan of Merger (the " Merger Agreement ")”

Oak Woods Acquisition Corp amended Merger Agreement with Oak Woods Merger Sub, Inc., Huajin (China) Holdings Limited, Xuehong Li (effective 2024-06-28).

“Because the parties to the Business Combination intend to continue to work to effectuate the Business Combination in furtherance of its prior filings, they have executed an agreement to extend the date by which a Business Combination is required to be completed to June 28, 2024.”

Neuraxis, INC amended SPA with Flagstaff International, LLC valued at $5 million (effective 2024-03-22).

“On March 22, 2024, the Company and Flagstaff entered into the third amendment to the SPA (the “Amendment”) to increase the investment amount from $3 million to $5 million”

Lumen Technologies, Inc. entered into Second Supplemental Indenture to Lumen 4.000% Senior Secured Notes due 2027 with Computershare Trust Company, N.A. valued at Eliminated restrictive covenants and released guarantees and security interests (effective 2024-03-22).

“On the Effective Date, Lumen, certain subsidiaries of Lumen party thereto and Computershare Trust Company, N.A., as trustee and notes collateral agent, entered into a second supplemental indenture to the indenture, dated as of January 24, 2020, governing Lumen’s 4.000% senior secured notes due 2027 (the “ Existing Lumen Notes ”), that, among other things, (i) eliminated substantially all of the restrictive covenants and certain events of default and (ii) released the guarantees of the Existing Lumen Notes and the security interests in the collateral securing such notes (the “ Lumen Supplemental Indenture ”).”

Lumen Technologies, Inc. entered into Amended and Restated Credit Agreement Amendment Agreement with Bank of America, N.A. valued at Amendment to Existing Lumen Credit Agreement; removed certain covenants, amended collateral agreemen (effective 2024-03-22).

“On the Effective Date, Lumen, as borrower, Bank of America, N.A. (“ BofA ”), as administrative agent and collateral agent, and the subsidiaries of Lumen, lenders and issuing banks party thereto entered into an amendment agreement (the “ Amendment Agreement ”) to that certain Amended and Restated Credit Agreement, dated as of January 31, 2020, among Lumen, the lenders and issuing banks party thereto and BofA, as administrative agent, collateral agent and swingline lender (as amended or otherwise modified prior to the date of the Amendment Agreement, the “ Existing Lumen Credit Agreement ” and, as amended, the “ Amended Lumen Credit Agreement ”).”

Lumen Technologies, Inc. entered into Superpriority Revolving/Term A Credit Agreement with Bank of America, N.A. valued at $489 million SP RCF-A, $467 million SP RCF-B, $377 million SP TLA (effective 2024-03-22).

“On the Effective Date, Lumen, as borrower, the lenders party thereto and BofA, as administrative agent and collateral agent, entered into the Superpriority Revolving/Term A Credit Agreement (the “ RCF/TLA Credit Agreement ”) providing for (i) a superpriority “first out” series A revolving credit facility with commitments of approximately $489 million (the “ SP RCF-A ”), (ii) a superpriority “second out” series B revolving credit facility with commitments of approximately $467 million (the “ SP RCF-B ”, and together with the SP RCF-A, the “ SP RCF ”) and (iii) a superpriority secured term loan facility in the amount of approximately $377 million (the “ SP TLA ”).”

Hempacco Co., Inc. entered into Securities Purchase Agreement with Mast Hill Fund, L.P. valued at $341,360 aggregate purchase price (effective 2024-03-26).

“Effective March 26, 2024, Hempacco Co., Inc. (the “ Company ”), entered into a securities purchase agreement (the “ SPA ”) with Mast Hill Fund, L.P., a Delaware limited partnership (“ Mast Hill ”), pursuant to which the Company sold, and Mast Hill purchased, (i) a convertible promissory note in the principal amount of $379,288.88 (the “ Note ”), and (ii) warrants to purchase 113,786 shares of Company common stock (the “ Warrants ”), for an aggregate purchase price of $341,360 (the “ Transaction ”), and the Company also entered into a registration rights agreement with Mast Hill (the “ RRA ”).”

Xilio Therapeutics, Inc. entered into Investor Rights Agreement with Gilead Sciences, Inc. (effective 2024-03-27).

“Pursuant to the terms of an investor rights agreement (the "Investor Rights Agreement") to be entered into between Gilead and the Company at the closing of the Initial Gilead Private Placement”

Xilio Therapeutics, Inc. entered into Stock Purchase Agreement with Gilead Sciences, Inc. valued at approximately $13.5 million (effective 2024-03-27).

“on March 27, 2024, the Company entered into a stock purchase agreement with Gilead (the "Stock Purchase Agreement") pursuant to which the Company agreed to initially issue and sell 6,860,223 of its shares of Common Stock to Gilead in a private placement at a purchase price of $1.97 per share for an aggregate purchase price of approximately $13.5 million”

Xilio Therapeutics, Inc. entered into License Agreement with Gilead Sciences, Inc. valued at approximately $43.5 million in upfront payments (effective 2024-03-27).

“On March 27, 2024, Xilio Development, Inc. ("Xilio Development"), a wholly-owned subsidiary of Xilio Therapeutics, Inc. (the "Company"), entered into an exclusive license agreement (the "License Agreement") with Gilead Sciences, Inc. ("Gilead")”